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Abstract 
Microglial activation participates in white matter injury after cerebral hypoperfusion. However, the 
underlying mechanism is unclear. Here, we explore whether activated microglia aggravate white 
matter injury via complement C3-C3aR pathway after chronic cerebral hypoperfusion. 
Methods: Adult male Sprague-Dawley rats (n = 80) underwent bilateral common carotid artery 
occlusion for 7, 14, and 28 days. Cerebral vessel density and blood flow were examined by 
synchrotron radiation angiography and three-dimensional arterial spin labeling. Neurobehavioral 
assessments, CLARITY imaging, and immunohistochemistry were performed to evaluate activation 
of microglia and C3-C3aR pathway. Furthermore, C3aR knockout mice were used to establish the 
causal relationship of C3-C3aR signaling on microglia activation and white matter injury after 
hypoperfusion. 
Results: Cerebral vessel density and blood flow were reduced after hypoperfusion (p<0.05). Spatial 
learning and memory deficits and white matter injury were shown (p<0.05). These impairments 
were correlated with aberrant microglia activation and an increase in the number of reactive 
microglia adhering to and phagocytosed myelin in the hypoperfusion group (p<0.05), which were 
accompanied by the up-regulation of complement C3 and its receptors C3aR (p<0.05). Genetic 
deletion of C3ar1 significantly inhibited aberrant microglial activation and reversed white matter 
injury after hypoperfusion (p<0.05). Furthermore, the C3aR antagonist SB290157 decreased the 
number of microglia adhering to myelin (p<0.05), attenuated white matter injury and cognitive 
deficits in chronic hypoperfusion rats (p<0.05).  
Conclusions: Our results demonstrated that aberrant activated microglia aggravate white matter 
injury via C3-C3aR pathway during chronic hypoperfusion. These findings indicate C3aR plays a 
critical role in mediating neuroinflammation and white matter injury through aberrant microglia 
activation, which provides a novel therapeutic target for the small vessel disease and vascular 
dementia. 
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Introduction 
Chronic cerebral hypoperfusion is closely related 
to cognitive impairment and vascular dementia [1, 2]. 
Increasing evidence indicates that chronic cerebral 
hypoperfusion could precede and contribute to white 
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matter injury, which is an important pathological 
feature of vascular dementia [3, 4]. Clinical studies 
have shown that white matter injury in vascular 
dementia is often more severe than that typically seen 
in Alzheimer's disease (AD) and Lewy body dementia 
[5-7]. In rodent, white matter damage is also a 
canonical feature of hypoperfusion [8, 9]. To explore 
the underlying mechanism, the rat model of bilateral 
common carotid artery occlusion (BCCAO) and 
mouse model of bilateral common carotid artery 
stenosis (BCAS) were used to mimic white matter 
injury during vascular dementia in humans [9-11]. 
Previous studies have suggested that 
neuroinflammation plays a crucial role in white 
matter injury and cognitive dysfunction induced by 
chronic cerebral hypoperfusion. Microglia are 
resident immune cells of the CNS that maintain brain 
homeostasis [12]. In pathological states, microglia 
could be activated to the detrimental phenotype 
which lead to tissue damage or transform into the 
protective phenotype secreting growth factors and 
promote tissue recovery. Their transcriptomic and 
proteomic profiles could be drastic different 
depending on the signals in the lesion 
microenvironment [13]. Phenotypic changes in 
microglia correlate with the prognosis of autoimmune 
demyelination disorders [14, 15]. Neuropathologic 
studies of white matter lesions have shown that 
robust neuroinflammatory responses are 
characterized by highly activated microglia [4, 16].  
Accumulated evidence shows the complement 
system plays a critical role in microglia-mediated 
effects during physiological and pathological 
processes [17]. The complement proteins C1q and C3 
mediate synapse elimination during development and 
neurodegeneration through C3-dependent microglia 
phagocytosis [18-20]. The classical complement 
pathway triggers microglia activation and induces 
early synaptic loss and dysfunction in AD [21]. C3 
deficiency suppresses microglia activation and 
protects against cognitive decline at later AD stages 
[22]. The activation of the complement system is also 
involved in white matter injury in multiple sclerosis 
[23]. C3a and C5a overexpression in the CNS 
aggravates the severity of cuprizone-induced white 
matter injury [24]. Knocking out C5 alleviates white 
matter lesions in the corpus callosum after chronic 
cerebral ischemia [25]. The complement cascade is 
also involved in acute cerebral vascular disease. 
Inhibiting the complement system reduces brain 
edema in the acute phase of hemorrhagic stroke and 
infarct volumes in acute ischemic stroke animals [26, 
27]. However, it is unclear whether and how 
complement-mediated microglia activation 
contributes to white matter injury after chronic 
cerebral hypoperfusion. We hypothesize that during 
chronic cerebral hypoperfusion, up-regulated 
complement C3 induces aberrant microglia activation 
and aggravates white matter injury through microglia 
movement to and phagocytosis of myelin. Our study 
could provide a novel therapeutic strategy for the 
small vessel disease and vascular dementia. 
Materials and Methods 
The animal experimental procedures were 
approved by the Institutional Animal Care and Use 
Committee (IACUC) of Shanghai Jiao Tong 
University, China. We performed all animal 
experiments in accordance with the ARRIVE 
guidelines. The experimental design is shown in 
Figure 1A. Cerebral vessel density and cerebral blood 
flow were determined by synchrotron radiation 
angiography (SRA) and three-dimensional arterial 
spin labeling at day 7, 14, and 28 after BCCAO. 
Neurobehavioral assessments were performed using 
the Morris water maze and novel object recognition 
tests. After C3aR antagonist treatment, 
immunostaining and behavioral studies were 
performed at day 14 and day 28. In C3aR knockout 
mice, immunohistochemical assessments were 
performed at day 28 after BCAS surgery.  
Animals 
Adult male Sprague-Dawley rats weighing 
250-300 g and C57BL/6 mice weighting 25 to 30 g 
(SLAC Laboratory Animals, Shanghai, China) were 
used in present study. Homozygous C3aR knockout 
mice (C.129S4-C3ar1tm1Cge/J, #005712, Jackson 
laboratory) weighting 25 to 30 g were used to evaluate 
C3-C3aR signaling on microglia activation and white 
matter injury in chronic cerebral hypoperfusion. Only 
male rodents were used in our study to exclude 
neuroprotection effect of estrogen on ischemic 
damage [28]. Animals were housed in groups of 4 to 
10, under a 12-hour light/12-hour dark cycle at 21 °C, 
50% humidity. Food and water were available ad 
libitum. Animal group size for behavioral or 
immunological studies was determined according to 
our preliminary results. Power analysis was 
performed using a type I error rate of 0.05 and a 
power of 80% on a two-sided test. Animals were 
randomly assigned to sham-operated or chronic 
cerebral hypoperfusion surgery groups at the 
beginning of each experiment. Animals in the BCCAO 
or BCAS group were subjected randomly to drugs or 
vehicle treatment. Independent cohorts were used for 
synchrotron radiation angiography and 
three-dimensional arterial spin labeling. Animals 
were coded with numbers, and experimenters were 
blinded to the treatment assignment. 
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Animal surgery  
Rats subjected to permanent bilateral common 
carotid artery occlusion (BCCAO) surgery and mice 
subjected to bilateral common carotid artery stenosis 
(BCAS) surgery were conducted as described 
previously [10, 29]. Briefly, the rats were anesthetized 
with 2% isoflurane in 0.5 L/min oxygen. Both 
common carotid arteries were ligated with two 5-0 
sutures (Covidien, Mansfield, MA). Mice were 
anesthetized with 1.5% isoflurane in a 30% O2/68.5% 
NO mixture, 0.18mm diameter microcoils (Sawane 
Spring Co., Shizuoka, Japan) are placed at both 
common carotid arteries just below the carotid 
bifurcation. Sham animals underwent bilateral 
common carotid artery exposure but not artery 
occlusion or stenosis. SB290157 (Merck Millipore, 
Darmstadt, Germany, #559410), a specific C3a 
receptor antagonist [30], was diluted in sterile 
phosphate-buffered saline (PBS)/2% DMSO to a 
concentration of 1 nM. Intraperitoneal injections of 
SB290157 (1 mg/kg) or 2% DMSO (vehicle) were 
performed immediately after BCCAO and once a day 
for 28 days. Intraperitoneal injection of minocycline 
(MedChemExpress, Monmouth, NJ, #HY-17412), an 
inhibitor of microglial activation, at a dose of 25 
mg/kg was performed immediately after BCCAO 
surgery and once a day for 28 days to attenuate 
microglia activation. Intraperitoneal injections of 
PLX3397 (MedChemExpress, Monmouth, NJ, 
#HY-16749), colony-stimulating factor 1 receptor 
(CSF1R) inhibitors at a dose of 1 mg/kg was 
performed immediately after BCAS surgery and twice 
a day for 28 days to eliminating microglia according 
to the instruction. 
Synchrotron radiation angiography 
SRA was performed at beam line 13W at the 
Shanghai Synchrotron Radiation Facility (SSRF), 
Shanghai, China. The imaging parameters and 
procedures were described previously [31]. Briefly, an 
angiographic tube (PE-10 catheter linked with PE-50 
catheter) linked with a 10-mL syringe was carefully 
inserted from the distal external carotid artery to the 
bifurcation of the internal carotid artery and the 
external carotid artery for injecting contrast agent. The 
syringe was connected to a microinjection system 
consisting of a precise injection pump (Longerpump, 
Baoding, China). The energy of the X-ray was 33.2 
KeV. Nonionic iodine contrast agent (300 mg/ml, 
Omnipaque, GE, Milwaukee, WI) was injected into 
the external carotid artery reversed at an injecting 
speed of 133.3 μl/s, with a resulting volume of 150 μl. 
The Charge Coupled Device (CCD) with 6.5 μm 
resolution (Photonic Science, East Sussex, UK) was 
placed 65 cm away from the animal. Ten consecutive 
images taken before contrast-enhancement were 
subtracted from raw images taken after injection to 
eliminate the background structure. The images 
obtained were then processed with MATLAB 
(Mathworks, Natick, MA) and stitched with Adobe 
Photoshop CS6 (Adobe, San Jose, CA). 
Magnetic resonance imaging 
MRI experiments were conducted with a 
Discovery 750 3.0 T scanner with a small animal wrist 
coil (GE Healthcare, Milwaukee, WI). The animals 
were anesthetized with 7% chloral hydrate (0.3 
ml/100 g) and placed in a supine position before 
scanning. The imaging parameters for the 3D ASL 
series were as follows: field of view = 120 mm × 120 
mm, matrix = 512 (points) × 12 (arms); 15 slices (each 4 
mm thick) were acquired in ascending order with no 
gap between slices; labelling duration = 1,650 ms; 
post-labeling delay = 1,025 ms; repetition time = 4,132 
ms; echo time = 11 ms; number of excitations = 5; 
bandwidth = 62.5 kHz; scan duration = 14 min 14 s. 
Cerebral blood flow was automatically calculated 
using Functool 3D ASL (GE Medical Systems, 
Milwaukee, WI). For the quantification of cerebral 
blood flow, the following equation was used: 
𝐶𝐶𝐶𝐶𝐶𝐶 = 𝜆𝜆 �1 − e−𝑡𝑡𝑠𝑠𝑠𝑠𝑠𝑠𝑇𝑇1𝑔𝑔 �2𝑎𝑎𝑇𝑇1𝑏𝑏 �1 − e −𝜏𝜏𝑇𝑇1𝑏𝑏�  𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 e−𝑃𝑃𝑃𝑃𝑃𝑃𝑇𝑇1𝑏𝑏  
In the equation, T1b was T1 of blood (1,600 ms); 
T1g, T1 of gray matter (1,200 ms); α, the labelling 
efficiency (0.95); λ, the cortex–blood partition 
coefficient (0.9); tsat, the time of saturation performed 
before imaging (2,000 ms); τ, the labeling duration 
(1,500 ms); and PLD, the post labeling delay time 
(1,025 ms). 
Neurobehavioral assessments 
Control and BCCAO rats treated with the C3aR 
antagonist or 2% DMSO underwent both the Morris 
water maze test and novel object recognition test on 
day 7, 14, 28. All tests were monitored and 
quantitatively analyzed by behavioral tracking system 
(Stoelting Co., Wood Dale, IL). The Morris water 
maze and novel object recognition tests were 
performed as previously described [32, 33]. All trials 
were performed in a quiet room with indirect lighting. 
The Morris water maze test was performed in a 
circular tank with a diameter of 170 cm, containing 
water at approximately 20-22 ℃. The swimming pool 
was virtually divided into four equal quadrants. The 
edible pigment was used to opacity the water to 
camouflage the submerged platform. The hidden 
circular platform (9 cm in diameter) was submerged 
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1.5 cm below the water surface and remained fixed 
throughout the spatial acquisition trials.  
The spatial acquisition trials were conducted 
over five consecutive days. Each trial had a maximum 
time of 2 min with an interval of 15 s between trials, 
four trials were completed per day. The animal was 
placed in one of four designated start positions in the 
maze, facing the sidewalls of the swimming pool. If 
the animal failed to reach the platform within 2 min, it 
was guided to the platform using a guide stick. After 
the animal reached the escape platform, it remained 
on the platform for 15 s before the beginning of the 
next trial. The escape latency was defined as the time 
that the animal spent to reach and climb onto the 
escape platform from the start position. On day 6, the 
probe test was conducted. The escape platform was 
removed from the pool and the animals could swim 
for 60 s. The percentage time spent in the target 
quadrant and the number of times that the animal 
crossed the zone where the platform formerly existed 
were recorded. Following probe test, Four-day 
working memory tests were performed. The platform 
was moved each day and each animal was given 2 
trials per day (Figure S4A). Trial 1 was the sample 
trial to learn the new location of the platform, and trial 
2 was performed for recall and the temporary 
memory measurement after a 15 seconds of inter-trial 
interval.  
In the novel object recognition test, rats were 
placed in a 45 cm (long) × 45 cm (wide) × 45 cm 
(height) sized box, and were permitted to explore the 
testing area for 10 min per day over a course of 3 days. 
After an interval of 24 h, two same objects were placed 
in the testing area for each animal to explore for 10 
min before being returned to the cage. After a 1-hour 
interval, one of the objects was replaced with a new 
one, and the rat explore the testing area once again 
but for 3 min. Novel object exploration was registered 
if the center of the rat’s head was oriented within 45° 
of the new object and within 4 cm of it. Climbing over 
or sitting on an object was not included. 
Discrimination time was computed as the time spent 
at the old object subtracted from the time spent at the 
novel one. 
Western blot analysis 
Protein (30 μg) from the striatum was loaded 
onto a 10% resolving gel for electrophoresis. Proteins 
were transblotted onto a polyvinylidene difluoride 
(PVDF) membrane (Merck Millipore) and then 
immuno-probed with primary antibodies to rat 
anti-myelin basic protein (MBP, Abcam, Cambridge, 
UK, ab7349, 1:1000), rabbit anti-CD86 (Abcam, 
ab112490, 1:1000), rabbit anti-iNOS (Abcam, ab15323, 
1:500), rat anti-Fc RII/III receptor (CD16/32, BD 
Pharmingen, San Diego, CA, 553142, 1:1000), rabbit 
anti-C3 (Abcam, ab200999, 1:1000), rabbit anti-ITGAM 
(Abcam, ab133357, 1:1000), goat anti-Arginase-1 
(Santa Cruz Biotechnologies, Dallas, TX, sc-18351, 
1:500), mouse anti-C3aR (Santa Cruz Biotechnologies, 
sc-133172, 1:500), rabbit anti-phospho-STAT3 (Tyr705) 
(Cell Signaling Technology, Danvers, MA, 9145, 
1:1000), rabbit anti-STAT3 (Cell Signaling Technology, 
4904, 1:1000), mouse anti-β-actin (Invitrogen, 
Carlsbad, CA, MA5-15739, 1:1000). The blots were 
incubated with horseradish peroxidase-conjugated 
IgG secondary antibody (Hua’an, Hangzhou, China) 
and then reacted with an enhanced 
chemiluminescence substrate (Pierce, Rockford, IL). 
The chemiluminescence results were recorded with an 
imaging system (Bio-Rad, Hercules, CA). 
Quantitative reverse transcriptase PCR  
Total RNA from the striatum was isolated using 
TRIzol reagent (Invitrogen, #15596026) according to 
the manufacturer’s protocol. Amplification was 
performed with a fast real-time PCR system (7900HT, 
ABI, Foster, CA) and a SYBR Premix Ex Taq Kit 
(TaKaRa, Dalian, China, #RR420L); RNA integrity 
was verified by electrophoresis on a 2% agarose gel. 
mRNA levels were normalized to the expression of 
endogenous control GAPDH in triplicate and were 
calculated by the 2-ΔΔCt method. The gene-specific 
primer sequences used were as follows: Cd86 (FW, 
AAGACATGTGTAACCTGCACCA; RV, TACGAGC 
TCACTCGGGCTTA),  Cd16  (FW, AGGGATCATTG 
GACGCAACA; RV, GACTCCTCTGCACCGAGAA 
A), Inos (FW, CACAGTGTCGCTGGTTTGAA; RV, 
TCTCCGTGGGGCTTGTAGT), Il-6 (FW, GGTTTGCC 
GAGTAGACCTCA; RV, TACCCCAACTTCCAATG 
CTC), Tnf-α (FW, AGTCTGCACAGTTCCCCAAC; 
RV, TTAGGAAGACACGGGTTCCA), Il-1β (FW, TG 
ATCGGTCCCAACAAGGAG; RV, TCCGCTTGGTG 
GTTTGCTAC), C1qa (FW, GCACTGTGCTTCAATTG 
CAACGAG; RV, GAAGATGCTGTCGGCTTCAGTA 
CC), C1qb (FW, GTTCTCACCTTCTGCGACTATGCC; 
RV, GTGAACAACCTCTTCCTGCTCCAG), C4b (FW, 
ATGATATGCCAGCCGCAGATGAC; RV, CAGGTT 
ACCGTTCCGCCAGATG), C3 (FW, CGTGCTGATCG 
AGGATGGTT; RV, ACTTCCCCACTAGGGCTTCT), 
C3ar1 (FW, AGGCAATGGGCTGGTGCTGT; RV, 
CAGGAAGACACTGGCAAACAT), Itgam (FW, GAC 
TCCGCATTTGCCCTACT; RV, TGCCCACAATGAG 
TGGTACAG), Gapdh (FW, GATGGTGAAGGTCG 
GTGTGA; RV, TGAACTTGCCGTGGGTAGAG). 
Tissue immunostaining 
 30-µm-thick free-floating brain sections were 
blocked by 10% fetal horse serum for 1 h. The sections 
were incubated in primary antibody solutions 
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overnight at 4 °C. Rat anti-MBP (Abcam, ab7349, 
1:400), mouse anti-SMI32 (Biolegend, San Diego, CA, 
801701, 1:100), rabbit anti-APC (Abcam, ab72040, 
1:50), rabbit anti-Iba-1 (Wako, Richmond, VA, 
019-19741, 1:300), rabbit anti-CD86 (Abcam, ab112490, 
1:200), mouse anti-CD68 (AbD Serotec, MCA341, 
1:200), rabbit anti-C3 (Abcam, ab200999, 1:200), mouse 
anti-ITGAM (AbD Serotec, Oxford, UK, MCA618, 
1:100), rat anti-C3aR (Hycult Biotech, Uden, 
Netherlands, HM1123, 1:100) antibodies were used. 
The sections were then incubated with secondary 
antibodies (Invitrogen, 1:200) at room temperature for 
1 h before imaging.  
CLARITY 
Rat brain clearing procedures were performed 
according to an optimized CLARITY protocol [34, 35]. 
For immunostaining, the 500-μm-thick brain slices 
were incubated with Rat anti-MBP (Abcam, ab7349, 
1:200) and rabbit anti-Iba-1 primary antibodies 
(Wako, 019-19741, 1:200) for 3 days at 37 °C with 
shaking. The samples were then incubated with 
secondary antibodies (Invitrogen, 1:200) at 37 °C for 
an additional 2 days. Subsequently, the samples were 
incubated in refractive index matching solution 
(RIMS, 88% HistodenZ, Sigma-Aldrich, St. Louis, MO, 
#D2158) for 1 h at room temperature before sample 
mounting. The samples were protected from light 
during all CLARITY steps. 
Image acquisition and processing 
The 30-µm-thick free-floating brain section and 
500-μm-thick clarified rat brain slice samples were 
imaged using a Nikon A1RMP confocal laser scanning 
microscope (Nikon Instruments Inc., Tokyo) 
equipped with a 25× water-immersion objective 
(Nikon CFI Apo NIR, numerical aperture = 1.0, 
working distance = 2.8 mm). For CLARITY samples, 
the imaging volume was 504 μm×504 μm×440 μm 
with a voxel size of 1.01 μm×1.01 μm×1.00 μm. 
NIS-Elements AR (Nikon Instruments Inc., Tokyo) 
was used to create three-dimensional volume 
renderings for myelin and microglia. The image 
resolution was 512×512. All images were acquired 
and processed by a researcher blinded to the 
experiment design.  
Quantitative analysis 
The quantification of immunostaining positive 
cells in the striatum was performed and data were 
presented as the number of positive cells and percent 
stained area per field, respectively. The quantification 
of SMI32/MBP ratio in the striatum was processed by 
ImageJ and fluorescence intensity in each field was 
quantified. The quantification of the distribution of 
microglia (Iba-1+) around myelin sheaths (MBP+) was 
performed by counting the number of microglia cell 
bodies that touched and localized within each myelin 
(MBP+) in the striatum. The ratio of microglia in 
contact with myelin relative to the amount of myelin 
in each image field was calculated. This accounted for 
the difference in the number of myelin fragments in 
different image fields and was considered to represent 
changes in the redistribution pattern of microglia in 
relation to myelin. For the quantification of the 
distribution of CD86+ microglia around each myelin 
fiber (MBP+), a region of interest (ROI) was drawn 
encompassing two concentric circles starting from the 
diameter of each myelin and ending at a 15-μm 
ascending radius. Threshold was set and the area 
(μm2) of CD86+ puncta within each ROI was 
quantified. For the quantification of the deposition of 
C3 puncta on each myelin fiber (MBP+), a region of 
interest encompassing each myelin within the 
striatum was drawn. Threshold was set and the area 
(μm2) of C3+ puncta within each myelin was 
quantified. For each rat, at least 4 images at 25× 
magnification were counted, which were derived 
from 4 fixed-frozen coronal sections spaced 100 µm 
apart. All quantifications were performed in 
NIS-Elements AR analysis software (Nikon 
Instruments Inc., Tokyo). Quantitative analyses of 
CLARITY images were performed using our 
customized MATLAB code. The procedures were 
described previously [35]. For each animal, at least 6 
regions of interest in the striatum at 25× magnification 
were counted. The percent of microglia in contact 
with myelin relative to the amount of myelin in the 3D 
volume was calculated. Image quantification and 
analyses were performed by researchers blinded to 
group assignments. 
Statistical analysis 
Descriptive statistics are presented as the mean ± 
standard deviation (SD). The normal distribution of 
data was examined by the Kolmogorov-Smirnov test. 
Results from Morris water maze spatial learning tests 
were compared by repeated measures two-way 
ANOVA. For all other comparisons among different 
groups, Student’s t-test or one-way ANOVA followed 
by Newman-Keuls post hoc test (homogeneity of 
variance) or Dunnett’s post hoc test (heterogeneity of 
variance) were used. For nonparametric analysis, 
Mann-Whitney U-test and Kruskal-Wallis test 
followed by Dunnett’s post hoc analysis were used. 
Statistical analyses were performed using SPSS 
software (version 17.0, SPSS, Chicago, IL). Two-tailed 
P values less than 0.05 were considered statistically 
significant. 
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Results 
Cerebral vessel density and dynamic cerebral 
blood flow decreased after BCCAO 
Synchrotron radiation angiography (SRA) 
indicated the formation of collaterals at day 28 after 
BCCAO (Figure 1B). This included the internal 
carotid artery to the ophthalmic artery and the 
internal carotid artery to the pterygopalatine artery. 
The quantitative results showed that the diameters of 
the anterior cerebral artery, middle cerebral artery, 
and posterior cerebral artery increased from day 7 to 
day 28 after BCCAO (p< 0.0001 for the anterior 
cerebral artery; p= 0.001 for the middle cerebral artery; 
p< 0.0001 for the posterior cerebral artery, Figure 1C). 
Compared with those in the control group, the 
densities of the cerebral vessels decreased after 
BCCAO (p< 0.0001, Figure 1C). 
Three-dimensional arterial spin labeling was 
used to monitor the dynamic changes in cerebral 
blood flow. The cerebral blood flow of the whole brain 
decreased to 50 ± 9.3% of the baseline level at day 7 
after BCCAO (p< 0.0001) and remained at 58 ± 20.4% 
of the baseline level at day 14 after BCCAO (p= 0.002). 
At day 28 after BCCAO, the cerebral blood flow of the 
whole brain was 112 ± 26.5% of the baseline level, 
which may be due to collateral opening (p= 0.750, 
Figure 1D). Furthermore, we found that cerebral 
blood flow changes in the cortex and striatum were 
consistent with those in the whole brain. 
 
 
Figure 1. Experimental design and BCCAO-induced cerebral vessel and dynamic cerebral blood flow changes. A Experimental design. BCCAO surgery was 
performed at day 0, and the animals were sacrificed at day 7, 14, and 28 after BCCAO. B Representative images of SRA in control and BCCAO rats at day 7, 14, and 28 after 
surgery. n = 6-12 animals in each group. Scale bar=1 mm. C Quantification of arterial diameters and cerebral vascular density in control and BCCAO rats at day 7, 14, and 28 after 
surgery. D Representative 3D arterial spin labeling images in rats at baseline and day 7, 14, and 28 after BCCAO and dynamic cerebral blood flow changes in the cortex and 
striatum in BCCAO rats at day 7, 14, and 28 after surgery, relative to baseline levels. n = 7 animals. The data are shown as the mean ± SD. ***, p< 0.001; **, p< 0.01; *, p< 0.05; 
NS, not significant; the BCCAO group vs. the control group. 3D ASL: 3D arterial spin-labeled imaging; ICA: internal carotid artery; MCA: middle cerebral artery; PCA: posterior 
cerebral artery. 
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BCCAO induced spatial learning and memory 
impairments and white matter injury 
The Morris water maze test was used to evaluate 
spatial learning and memory performance in BCCAO 
and control rats. The quantitative data showed that 
the latency to the platform was longer at day 14 and 
day 28 after BCCAO compared with the controls in 
the spatial acquisition test (p= 0.020 for day 14 and p= 
0.002 for day 28, Figure S1A). We also found that the 
percentage time in the target quadrant was lower at 
day 28 (p= 0.049) but not day 14 (p= 0.839) after 
BCCAO compared to the controls in the probe test 
(Figure S1B). However, no differences were found in 
spatial learning or memory performance between 
BCCAO and control rats at day 7 after surgery (p= 
0.160 for spatial learning test and p= 0.813 for spatial 
memory test, Figure S1A and S1B). The data 
indicated that BCCAO rats exhibited spatial learning 
and memory deficits beginning at day 14 and lasting 
to day 28. Furthermore, working memory was 
evaluated in BCCAO and controls rats after 28 days of 
surgery. The latency to the platform was longer on 
day 1 of the test in BCCAO rats compared to the 
controls (p= 0.022, Figure S4B), which suggested that 
chronic cerebral hypoperfusion also induced working 
memory impairment. 
Since cognitive dysfunction in chronic ischemia 
is associated with white matter injury [4, 9], we 
investigated the expression of the myelin marker 
myelin basic protein in BCCAO and control rats. The 
quantitative results showed that MBP protein levels in 
the striatum were lower in BCCAO rats than in 
control rats from day 7 to day 28 (p= 0.0002, Figure 
S1C). Moreover, the fluorescence intensity of SMI32 
increased and APC decreased in the striatum of 
BCCAO rats compared to the control rats (p= 0.013 for 
SMI32; p< 0.001 for APC, Figure S1D), which 
indicated that BCCAO induced axonal and 
oligodendrocyte damage. In addition, quantification 
of MBP immunostaining in five additional tested 
white matter regions showed consistent myelin 
degradation after hypoperfusion (p< 0.05 for all tested 
region, Figure S2). These data demonstrated that 
BCCAO induced white matter injury starting at day 7 
and sustained for at least 28 days. 
Increased reactive microglia and 
neuroinflammation in BCCAO rats 
We further evaluated whether microglia are 
activated after surgery. We found that Iba-1+ cells in 
the striatum exhibited small soma and ramified 
processes before surgery. After surgery, microglia 
displayed enlarged cell bodies with rarefied and 
shortened processes, which are characteristic 
morphology of activated microglia (Figure 2A). The 
number of Iba-1+ cells in the striatum was increased at 
day 14 after surgery compared to the controls (p= 
0.014, Figure 2A). The mRNA and protein expression 
of pro-inflammatory microglia markers CD86, CD16, 
and iNOS in the striatum were up-regulated in 
BCCAO rats compared with that in control rats (p= 
0.015 for Cd86 mRNA; p= 0.013 for Cd16 mRNA; p< 
0.001 for Inos mRNA; p= 0.006 for CD86 protein; p= 
0.007 for CD16 protein; p= 0.003 for iNOS protein, 
Figure 2B and 2C). The mRNA levels of the 
pro-inflammatory cytokines IL-6, TNF-α, and IL-1β in 
the striatum were also significantly increased in 
BCCAO rats compared to those in control rats (p= 
0.001 for Il-6; p= 0.001 for Tnf-α; p= 0.001 for Il-1β, 
Figure S3A). Furthermore, the number of CD86+ cells 
was increased in BCCAO rats (p= 0.026, Figure 2D). 
But no significant difference was found in the protein 
levels of the anti-inflammatory marker Arginase-1 in 
the striatum between BCCAO and control rats (p= 
0.203, Figure S3B). These data suggested that 
microglia activated towards detrimental phenotype 
and induced neuroinflammation after hypoperfusion. 
Reactive microglia redistributed and 
phagocytosed myelin in the striatum of 
BCCAO rats 
Chemotaxis and phagocytosis are two major 
functions of microglia. We investigated whether these 
functional behaviors of microglia were involved in 
ischemic white matter injury. Quantification of the 
microglia proportion in contact with the myelin fibers 
showed an increasing tendency from day 7 to day 14 
after BCCAO surgery compared to controls (p= 0.012, 
Figure 3A), suggesting microglia moved towards 
myelin after BCCAO surgery. Furthermore, to 
determine the spatial distribution of microglia relative 
to myelin in the striatum, the CLARITY imaging 
method was used. At day 14 after surgery, compared 
with control rats, BCCAO rats displayed an uneven 
distribution of microglia, and more microglia were in 
contact with the myelin fibers in the striatum (p= 
0.021, Figure 3B and Suppl. Movie 1).  
To further analyze the phenotype of the 
microglia adhering to myelin and their role, we used 
triple-staining of MBP with the pro-inflammatory 
marker CD86 and the lysosomal proteins CD68 in 
BCCAO and control rats (Figure 3C). The results 
showed significantly increased levels of CD86 
immunoreactivity around each myelin after BCCAO 
surgery (p= 0.011, Figure 3C). Furthermore, 
phagocytotic microglia (CD68+) in contact with 
myelin also tended to increase after BCCAO surgery 
(p= 0.023, Figure 3C). The colocalization of CD68 and 
CD86 suggested that phagocytotic activity of the 
reactive microglia increased after BCCAO surgery 
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(Figure 3C) and accompanied by decreased myelin 
fibers in the striatum. Taken together, these results 
suggested that aberrant activated microglia 
redistributed and phagocytosed myelin to aggravate 
white matter injury. 
 
 
 
Figure 2. Aberrant activated microglia increase in BCCAO rats. A Representative images and quantification for the number of Iba-1+ microglia cells (red) in the striatum 
of control and BCCAO rats at day 7, 14, and 28 after surgery. n = 3-4 animals in each group. Scale bar=50 μm. B Quantitative RT-PCR analysis of the expression of Cd86, Cd16, 
and Inos in the striatum of control and BCCAO rats at day 7, 14, and 28 after surgery. The values are normalized to those of the control group. n = 3-6 in each group. C Western 
blots and quantification for CD86, CD16, iNOS, and β-actin in the striatum of BCCAO and control rats at day 7, 14, and 28 after surgery. n = 3 in each group. D Representative 
images and quantification of reactive microglia (CD86+ cells, red) in the striatum of BCCAO and control rats. n = 3-4 animals in each group. Scale bar=50 μm. The data are shown 
as the mean ± SD. ***, p< 0.001; **, p< 0.01; *, p< 0.05; NS, not significant; the BCCAO group vs. control group. 
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Figure 3. Microglia redistribute and phagocytose myelin in the striatum of BCCAO rats. A Representative images and quantification of the proportion of microglia 
cells (Iba-1+ cells, red) adhered to myelin (MBP+, green) relative to the number of myelin fibers in the striatum of control and BCCAO rats. Scale bar=50 μm. B CLARITY analysis 
of 500-μm-thick rat brain slice co-stained with Iba-1 and MBP in control and BCCAO rat at day 14 after surgery. The volumes of representative 3D visualization are 309 μm×309 
μm×200 μm, with a voxel size of 1.01 μm×1.01 μm×1.00 μm. Scale bar=100 μm. C Triple immunostaining and quantification of reactive (CD86+ cells, red) and phagocytic 
microglia cells (CD68+ cells, indigo) adhered to myelin (MBP+, green) in the striatum of control and BCCAO rats at day 7, 14, and 28 after surgery. Images at the bottom are 
magnified views of the areas in the upper of the images. Scale bar=50 μm for images at the top, Scale bar=10 μm for images at the bottom. n = 3-4 animals in each group. The data 
are shown as the mean ± SD. **, p< 0.01; *, p< 0.05; NS, not significant; the BCCAO group vs. control group. 
 
Activation of the C3-C3aR/ITGAM pathway in 
BCCAO rats  
Microglias express high levels of ITGAM (also 
known as CR3 or CD11b) immunoreactivity which are 
up-regulated under chronic cerebral ischemia [12]. 
Since ITGAM is one of the receptors of complement 
component C3, we determined whether the 
C3-C3aR/ITGAM signaling pathway was involved in 
white matter injury after BCCAO injury. The mRNA 
and protein levels of complement C3 and its receptors 
C3aR and ITGAM in BCCAO rats were examined. In 
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addition, the mRNA levels of major complement 
components C1qa, C1qb, C4b were also detected. The 
results showed that the mRNA levels of complement 
components C1qa, C1qb, C3, C4b were increased in 
BCCAO rats (p< 0.0001 for C1qa mRNA comparison; 
p= 0.002 for C1qb mRNA comparison; p= 0.012 for C3 
mRNA comparison; p= 0.005 for C4b mRNA 
comparison; Figure 4A). C3 protein levels in the 
striatum were also increased in BCCAO rats 
compared with those in control rats (p< 0.0001, Figure 
4B). Moreover, the mRNA and protein levels of 
ITGAM in the striatum were increased in BCCAO rats 
at day 7 and day 14 after surgery compared to those in 
control rats (p= 0.001 for mRNA comparison; p= 
0.0005 for protein comparison, Figure 4A and 4B). 
Importantly, we found that C3 deposition on myelin 
fibers dramatically increased after BCCAO surgery 
(p< 0.0001, Figure 4C). At the same time, the mRNA 
and protein levels of C3aR, another receptor of 
complement C3, were significantly up-regulated after 
BCCAO surgery (p = 0.021 for mRNA comparison; p= 
0.0005 for protein comparison, Figure 4A and 4B). 
These results indicated that the C3-C3aR/ITGAM 
pathway was activated after BCCAO injury. 
 
 
 
Figure 4. Activation of complement C3-C3aR/ITGAM pathway in BCCAO rats. A Quantitative RT-PCR analysis of the expression of C1qa, C1qb, C4b, C3, C3ar, and 
Itgam in the striatum of control and BCCAO rats at day 7, 14, and 28 after BCCAO surgery. The values are normalized to those of the control group. n = 3-7 in each group. B 
Western blots and quantification for C3, C3aR, ITGAM, and β-actin in the striatum of control and BCCAO rats at day 7, 14, and 28 after surgery. C Representative images and 
quantification of complement C3 puncta (red) deposition on myelin (MBP+, green) in the striatum of BCCAO and control rats. n = 3-4 animals in each group at day 7, 14, and 28 
after surgery. Scale bar=10 μm. The data are shown as the mean ± SD. ***, p< 0.001; **, p< 0.01; *, p< 0.05; NS, not significant; the BCCAO group vs. the control group. 
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Figure 5. Genetic deletion of C3ar1 attenuates microglia activation and reverses white matter injury in BCAS mice. A Representative images and quantification 
of C3aR (green) and Iba-1 (red) double-positive cells and microglia cells (Iba-1+ cells, red) in the striatum of WT, C3aR-KO, BCAS, and BCAS/C3aR-KO mice at day 28 after 
surgery. Scale bar=25 μm. B Western blots and quantification for CD86, iNOS, MBP and β-actin in the striatum of WT, C3aR-KO, BCAS, and BCAS/C3aR-KO mice at day 28 
after surgery. C Representative images and quantification of damaged axon (SMI32+, red) relative to myelin (MBP+, green) and mature oligodendrocyte (APC+ cells, red) in the 
striatum of WT, C3aR-KO, BCAS, and BCAS/C3aR-KO mice at day 28 after surgery. Scale bar=50 μm. D Western blots of total- and phospho-STAT3 (pSTAT3) and β-actin in 
the striatum of WT, C3aR-KO, BCAS, and BCAS/C3aR-KO mice at day 28 after surgery. E and F Quantification of total STAT3/ β-actin (E) and phospho-STAT3/STAT3 (F) 
levels in the striatum of WT, C3aR-KO, BCAS, and BCAS/C3aR-KO mice at day 28 after surgery. The data are shown as the mean ± SD. n = 3-4 animals in each genotype group. 
***, p< 0.001; **, p< 0.01; *, p< 0.05; NS, not significant. 
 
C3ar1 ablation alleviated microglia activation 
and white matter impairment in BCAS mice 
Complement component C3 must be split into its 
cleavage products C3a and iC3b to execute its 
biological function [36]. We hypothesized that the 
up-regulation of C3 would mediate microglial 
activation and chemotaxis towards myelin fibers by 
binding C3aR on microglia membrane. Subsequently, 
microglia opsonize myelin fragments for elimination 
through ITGAM. C3aR/Iba-1 double-staining 
revealed predominantly increases C3aR fluorescence 
in Iba-1-positive area in BCAS mice (p< 0.0001, Figure 
5A). Then C3aR knockout mice were used to evaluate 
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C3-C3aR signaling on microglia activation and white 
matter injury after hypoperfusion. We found that the 
number of microglia was significantly decreased in 
C3aR knockout mice compared with those wild type 
after BCAS surgery (p< 0.001, Figure 5B). Genetic 
deletion of C3aR significantly down-regulated the 
expression of reactive microglial marker CD86 and 
iNOS protein levels in the striatum after BCAS 
surgery (p= 0.001 for CD86; p= 0.001 for iNOS, Figure 
5B). MBP protein levels were also recovered in the 
striatum of C3aR knockout mice after BCAS surgery 
(p= 0.007, Figure 5B). SMI32 and APC 
immunostaining results showed that C3aR ablation 
significantly rescued axon and oligodendrocyte in 
BCAS mice at day 28 after surgery (p= 0.0001 for 
SMI32; p= 0.012 for APC, Figures 5C). Moreover, 
deleting microglia by CSF1R inhibitor PLX3397 or 
inhibiting microglia activation by minocycline, axonal 
and oligodendrocyte degeneration were significantly 
reversed induced by chronic cerebral hypoperfusion 
(p< 0.01 for all comparisons, Figure S6 and S7). The 
results indicated that C3-C3aR pathway directly 
mediated aberrant microglia activation and white 
matter injury in chronic cerebral hypoperfusion. 
It is reported that STAT3 was a downstream 
target of C3-C3aR signaling pathway [37]. We 
detected phospho-STAT3 and STAT3 protein levels in 
our chronic hypoperfusion model. We found that 
genetic deletion of C3aR significantly inhibited STAT3 
phosphorylation in the striatum at day 28 after 
surgery (p= 0.0004, Figure 5D). The results suggested 
that C3aR mediated microglia activation via STAT3 
signaling. 
C3aR inhibition prevents microglial activation 
and redistribution after BCCAO  
SB290157, a specific antagonist of C3aR, was 
used to further evaluate the role of C3-C3aR signaling 
in mediating microglia activation and chemotaxis. 
Firstly, we monitored the dynamic CBF changes 
under C3aR inhibition in BCCAO and the control rats 
by using three-dimensional arterial spin labeling 
technique. The quantitative results showed that CBF 
of the whole brain decreased to 68.38 ± 11.27% of the 
baseline level at day 7 after BCCAO under C3aR 
inhibition (p< 0.05) and remained at 68.37 ± 15.06% of 
the baseline level at day 14 after BCCAO surgery 
under C3aR inhibition (p< 0.05). At day 28 after 
BCCAO surgery, CBF of the whole brain under C3aR 
inhibition was 72.07 ± 12.39% of the baseline (p< 0.05, 
Figure S5). No significant difference was found in 
CBF changes from day 7 to 28 between BCCAO rats 
with and without C3aR inhibition. We then 
determined the protein expression of reactive 
microglia markers CD86 and iNOS in the striatum of 
BCCAO rats treated intraperitoneally with SB290157 
or vehicle. The results showed that compared with 
vehicle injection, SB290157 treatment inhibited CD86 
and iNOS protein expression after BCCAO surgery 
(p= 0.002 for CD86; p= 0.002 for iNOS, Figure 6A).  
We further performed MBP/Iba-1 co-staining to 
evaluate whether C3aR inhibition affected microglia 
mobility towards myelin in BCCAO rats. Iba-1 
immunostaining showed that microglia exhibited 
shorter cellular processes without enlarged cell bodies 
in BCCAO rats treated with SB290157 compared with 
those treated with vehicle (Figure 6B), indicating that 
C3aR inhibition weakened the morphological change 
of microglia after hypoperfusion. Furthermore, 
compared with vehicle treatment, SB290157 treatment 
significantly decreased the proportion of microglia in 
contact with myelin in BCCAO rats (p= 0.008, Figure 
6C), suggesting that blocking C3aR pathway inhibited 
microglial movement towards myelin. However, 
SB290157 treatment did not significantly reduce the 
number of microglia in the striatum in comparison 
with vehicle treatment (p= 0.158, Figure 6D). These 
results indicated that targeting C3aR prevented 
microglia activation and redistribution in the striatum 
after BCCAO. 
C3aR inhibition prevents behavioral deficits 
and white matter injury in BCCAO rats 
To further determine whether SB290157 could 
alleviate cognitive impairment after BCCAO, Morris 
water maze and new object recognition tests were 
performed. Spatial learning and memory dysfunction 
were reversed by SB290157 treatment in BCCAO rats 
in the Morris water maze test (p= 0.002 for escape 
latency to the platform; p= 0.010 for the number of 
entries onto the platform; p= 0.006 for percentage time 
in the target quadrant, Figures 7A and 7B). SB290157 
treatment also led to a significant recovery of 
cognitive function after BCCAO in the new object 
recognition test (p= 0.013, Figure 7C). The results 
indicated that C3aR antagonist SB290157 could 
effectively alleviate cognitive impairment due to 
BCCAO surgery. 
Furthermore, MBP protein levels were recovered 
in BCCAO rats treated with SB290157 (p= 0.0002, 
Figure 7D). SMI32 and APC immunostaining results 
showed that SB290157 treatment significantly 
alleviated axonal and oligodendrocyte degeneration 
in BCCAO rats than that in controls after 28 days of 
surgery (p< 0.0001 for SMI32; p< 0.0001 for APC, 
Figure 7E and 7F). These results indicated recovery of 
white matter integrity after SB290157 treatment in 
BCCAO rats. 
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Figure 6. C3aR inhibition suppresses microglial activation and microglia redistribution to myelin in BCCAO rats. A Western blots and quantification for CD86, 
iNOS, and β-actin in the striatum of the sham+vehicle, sham+C3aR antagonist, BCCAO+vehicle, and BCCAO+C3aR antagonist groups. n = 3-6 in each group. B Representative 
images of microglia cells (Iba-1+ cells, red) contacting with myelin (MBP+, green) in the striatum of sham+vehicle, sham+C3aR antagonist, BCCAO+vehicle, and BCCAO+C3aR 
antagonist groups. Scare bar=50 μm. n= 3-4 in each group. C-D Quantification of the proportion of microglia cells adhered to myelin relative to the number of myelin fibers (C) 
and the number of microglia cells (D). The data are shown as the mean ± SD. ***, p< 0.001; **, p< 0.01; *, p< 0.05; NS, not significant; the BCCAO group vs. control group. 
C3aRA: C3aR antagonist. 
 
Discussion 
In the present study, we combined SRA with 
three-dimensional arterial spin labeling to detect 
cerebral vessel density and blood flow after BCCAO 
injury for the first time. Microglia were activated, 
which moved and adhered to myelin and 
phagocytosed myelin components to aggravate white 
matter injury via C3-C3aR pathway after chronic 
hypoperfusion. Furthermore, genetic deletion of 
C3ar1 and C3aR antagonist inhibited aberrant 
microglia activation and microglia redistribution to 
myelin and subsequently reversed white matter 
injury and cognitive deficits.  
Microglia can be activated by different signals in 
the micromilieu to trigger a pro-inflammatory or 
anti-inflammatory response, thus exacerbating tissue 
damage or promoting tissue repair [38]. In multiple 
sclerosis, microglia activation is correlated with 
detrimental clinical outcomes [39]. Inhibiting 
microglia activation to the pro-inflammatory 
phenotype could alleviate inflammatory injury, limit 
myelin loss in experimental autoimmune neuritis and 
chronic cerebral hypoperfusion [40, 41]. Our results 
support that detrimental microglia increase and 
release pro-inflammatory cytokines after BCCAO. 
Previous reports suggested that microglial 
phagocytosis of myelin debris is considered beneficial 
and a prerequisite for myelin regeneration and axonal 
growth [42, 43]. Our findings support the notion that 
reactive microglia expressing CD68 adhered to and 
engulfed the intact myelin fibers rather than the 
myelin debris. The active phagocytosis of myelin was 
concomitant with cognitive dysfunction, suggesting 
that myelin phagocytosis by microglia destroyed 
white matter integrity after BCCAO. 
Another important finding of our study is that 
the activation of the complement C3-C3aR pathway 
exacerbated white matter injury through microglia 
activation and redistribution in chronic cerebral 
hypoperfusion. Recent study has reported that 
complement component C5 is involved in white 
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matter injury in chronic cerebral ischemia [25]. In 
addition, a previous study showed that disrupting 
microglia specific C3/CR3 signaling resulted in 
sustained deficits in synaptic connectivity [44]. Our 
results indicate that increased C3 levels aggravate 
white matter injury after hypoperfusion via microglial 
C3a receptor.  
 
 
Figure 7. C3aR inhibition prevents behavioral deficits and white matter injury in BCCAO rats. A Five-day spatial learning performance measured as the latency to 
reach the platform in the Morris water maze test in sham+vehicle, sham+C3aR antagonist, BCCAO+vehicle, and BCCAO+C3aR antagonist groups. n= 12-15 animals for each 
group. B Spatial memory performance measured as the number of entries into the platform quadrant and the percentage of time spent in the platform quadrant in the Morris 
water maze test in the sham+vehicle, sham+C3aR antagonist, BCCAO+vehicle, and BCCAO+C3aR antagonist groups, n = 12-15 animals in each group. C Spatial memory 
performance measured as discrimination time in the new object recognition test in the sham+vehicle, sham+C3aR antagonist, BCCAO+vehicle, and BCCAO+C3aR antagonist 
groups. n = 4-6 animals for each group. D Western blots and quantification for myelin basic protein (MBP) and β-actin in the striatum of sham+vehicle, sham+C3aR antagonist, 
BCCAO+vehicle, and BCCAO+C3aR antagonist groups. E-F Representative images and quantification of damaged axon (SMI32+, red) relative to myelin (MBP+, green) (E) and 
mature oligodendrocyte (APC+ cells, red) (F) in the striatum of sham+vehicle, sham+C3aR antagonist, BCCAO+vehicle, and BCCAO+C3aR antagonist groups. n = 3-4 animals 
in each group. Scale bar=50 μm. The data are shown as the mean ± SD. **, p< 0.01; *, p< 0.05; the BCCAO group vs. control group. C3aRA: C3aR antagonist. 
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C3aR is expressed on neurons, microglia, 
astrocytes, endothelial cells, and stem cells, but its 
expression in neurons was not dramatically 
up-regulated during neuroinflammation [45]. In 
contrast, its expression in microglia was significantly 
up-regulated in disease models [37, 45, 46]. Inhibiting 
C3aR reduced neuroinflammation in AD mouse 
model [37]. In addition, C3aR-/- inhibits the activation 
of microglia, subsequently blocks the phagocytosis of 
presynaptic components in the hippocampus and 
reverses the cognitive impairments caused by West 
Nile virus infection [22]. We found that C3aR 
predominantly increased in Iba-1-positive cells and 
blocking C3aR pathway suppressed detrimental 
microglial activation and alleviated white matter 
injury and cognitive decline after hypoperfusion. 
Furthermore, treatment with the C3aR antagonist 
modified microglia morphology and inhibited 
microglial movement to myelin fibers. However, the 
present study does not rule out the possibility that 
up-regulation of C3aR may occasionally occur on 
neurons, astrocytes, and endothelial cells, the 
therapeutic effects of C3aR antagonists after 
hypoperfusion may occur indirectly by modulating 
the functions of these cell types. Further studies are 
needed to determine the contribution of these cell 
types to disease pathogenesis.  
In the present study, we found that genetic 
deletion of C3aR inhibited STAT3 phosphorylation in 
the striatum after hypoperfusion, suggesting that 
C3aR regulated microglia activation via STAT3 
signaling. This finding was consistent with a previous 
study reporting that STAT3 was a downstream target 
of C3-C3aR signaling and C3aR activates STAT3 
signaling in microglia of AD transgenic mice through 
direct and indirect mechanisms [37]. Considering the 
complex crosstalk among various immune pathways, 
other signaling pathways may work in parallel to 
augment the microglia activation in downstream of 
C3aR after hypoperfusion. Further study will be 
needed to identify their roles in complement 
C3aR-mediated microglia activation after 
hypoperfusion. 
CLARITY imaging and analysis system provide 
a powerful tool for thoroughly evaluating spatial 
structural and functional alteration of brain in rodent 
disease models. It facilitates antibody penetration into 
the brain by removing lipid bilayers, and permitted 
rounds of staining. In the present study, moreover, 
various fluorescent signal amplification systems were 
tried to improve antibody penetration throughout the 
thickness of the sample. We applied longer clearing 
time before antibody incubation, the higher 
concentration of antibodies. In addition, higher laser 
intensity was used to achieve high quality of 
signal-to-noise ratio in deep imaging of brain section. 
However, the inherent difficulty of poor antibody 
penetration into the thick brain sections still exists in 
this novel clearing technique. CLARITY-optimized 
whole brain staining method should be developed in 
future study.  
It is worth noting that our analysis mainly 
focused on the resident microglia in the CNS. 
Activated Iba-1-positive cells might also be infiltrated 
macrophages. Further studies using bone marrow 
(BM)-chimerism and dual-reporter transgenic fate 
mapping and next-generation sequencing are needed 
to distinguish the potential effect of infiltrated 
macrophages from resident microglia. 
In conclusion, the up-regulation of complement 
C3 expression activated the microglial membrane 
receptors C3aR, which induced aberrant microglia 
activation and mediated microglia redistribution and 
myelin engulfment in the striatum during chronic 
cerebral hypoperfusion. Pharmacological targeting of 
C3aR alleviated white matter injury and eventually 
reversed cognitive decline. Given that white matter 
impairment is a canonical feature of human 
small-vessel disease and vascular dementia, our study 
demonstrated a critical role of C3aR in mediating 
neuroinflammation and white matter injury through 
aberrant microglia activation, which provides a novel 
therapeutic strategy for the small-vessel disease and 
vascular dementia. 
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